CD69 and myeloid sarcoma: On the contrary and as expected, no activation of cells was observed in non-stimulated lymphocytes, in either the MS or the healthy control samples (2.31% CD69+ and 2.24% CD25+ in MS; and 6.04% CD69+ and 6.97% CD25+ in healthy control samples).